Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.50 |
| ▸ | PGR | P06401 | 4/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26654644 | 0.86 | MAP4K1 (0.52) | ALDH1A1NR3C1PGRMAP4K1 | |
| SCHEMBL1542061 | 0.82 | NR3C1 (0.55) | NR3C1PGRCYP11B2 | |
| SCHEMBL836503 | 0.81 | CYP11B1 (0.49) | ALDH1A1L3MBTL1NR3C1PGRCYP11B1 | |
| SCHEMBL30749607 | 0.81 | MAP4K1 (0.47) | ALDH1A1L3MBTL1NR3C1PGRCYP11B1 | |
| SCHEMBL27170740 | 0.81 | MAP4K1 (0.47) | ALDH1A1L3MBTL1NR3C1PGRCYP11B1 | |
| SCHEMBL1542086 | 0.79 | NR3C1 (0.57) | NR3C1PGRCYP11B2 | |
| SCHEMBL25230008 | 0.77 | NR3C1 (0.57) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL30947618 | 0.76 | CYP11B1 (0.56) | ALDH1A1L3MBTL1NR3C1PGRCYP11B1 | |
| SCHEMBL836751 | 0.76 | CYP11B2 (0.67) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL25366126 | 0.76 | MAP4K1 (0.47) | ALDH1A1L3MBTL1NR3C1PGRCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112299-A1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2308880-A1 | TETRACYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112299-A1 | TETRACYCLIC COMPOUND | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LPXN | ALDH1A1 3255/4885L3MBTL1 639/4885NR3C1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.